Form 4 for CADL Candel Therapeutics, Inc.
Accepted 2024-11-21 00:00:00 ET · period of report 2024-11-21 · accession 0000950170-24-129677 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-11-21 | 2024-11-21 | CADL | Tak Paul Peter | CEO, Dir | M - OptEx | $1.55 | +12.9K | 343.6K | +4% | +$20.0K |
| D | 2024-11-21 | 2024-11-21 | CADL | Tak Paul Peter | CEO, Dir | M - OptEx | $0.00 | -12.9K | 1.76M | -0.7% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-11-21 | M | A | 12,900 | $1.55 | 343,635 | D | — | — | |
| 2 | Derivative | Stock Option (Right to Buy) | 2024-11-21 | M | D | 12,900 | $0.00 | 1,763,968 | D | $1.55 · — to 2030-10-10 | 12,900 Common Stock | (F1) 25% of this option vested and became exercisable on October 10, 2020, with another 25% vesting on October 10, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter. |